vs
FIRST US BANCSHARES, INC.（FUSB）与STRATA Skin Sciences, Inc.（SSKN）财务数据对比。点击上方公司名可切换其他公司
FIRST US BANCSHARES, INC.的季度营收约是STRATA Skin Sciences, Inc.的1.1倍（$10.4M vs $9.3M），FIRST US BANCSHARES, INC.净利率更高（20.4% vs 0.6%，领先19.8%），FIRST US BANCSHARES, INC.同比增速更快（7.1% vs -3.0%），FIRST US BANCSHARES, INC.自由现金流更多（$9.1M vs $-551.0K），过去两年STRATA Skin Sciences, Inc.的营收复合增速更高（17.3% vs 2.6%）
第一美国银行控股公司是一家银行控股企业，核心子公司第一公民银行在美国23个州经营着超过500家网点，另一家子公司硅谷银行则在15个州设有39个办事处，是美国规模较大的银行机构之一，总部位于北卡罗来纳州罗利。
STRATA Skin Sciences是一家美国医疗器械企业，专注于设计、开发并商业化推出非侵入式检测工具，供皮肤科医生在进行黑色素瘤皮肤检查时获取更多辅助诊断信息。
FUSB vs SSKN — 直观对比
营收规模更大
FUSB
是对方的1.1倍
$9.3M
营收增速更快
FUSB
高出10.0%
-3.0%
净利率更高
FUSB
高出19.8%
0.6%
自由现金流更多
FUSB
多$9.6M
$-551.0K
两年增速更快
SSKN
近两年复合增速
2.6%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $10.4M | $9.3M |
| 净利润 | $2.1M | $58.0K |
| 毛利率 | — | 61.8% |
| 营业利润率 | 28.1% | 5.3% |
| 净利率 | 20.4% | 0.6% |
| 营收同比 | 7.1% | -3.0% |
| 净利润同比 | 24.2% | 101.3% |
| 每股收益（稀释后） | $0.36 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收FUSBSSKN
| Q4 25 | $10.4M | $9.3M | ||
| Q3 25 | $10.5M | $6.9M | ||
| Q2 25 | $10.3M | $7.7M | ||
| Q1 25 | $9.8M | $6.8M | ||
| Q4 24 | $9.7M | $9.6M | ||
| Q3 24 | $10.1M | $8.8M | ||
| Q2 24 | $10.0M | $8.4M | ||
| Q1 24 | $9.9M | $6.8M |
净利润FUSBSSKN
| Q4 25 | $2.1M | $58.0K | ||
| Q3 25 | $1.9M | $-1.6M | ||
| Q2 25 | $155.0K | $-2.6M | ||
| Q1 25 | $1.8M | $-2.1M | ||
| Q4 24 | $1.7M | $-4.6M | ||
| Q3 24 | $2.2M | $-2.1M | ||
| Q2 24 | $2.1M | $-91.0K | ||
| Q1 24 | $2.1M | $-3.4M |
毛利率FUSBSSKN
| Q4 25 | — | 61.8% | ||
| Q3 25 | — | 60.4% | ||
| Q2 25 | — | 56.2% | ||
| Q1 25 | — | 53.5% | ||
| Q4 24 | — | 61.4% | ||
| Q3 24 | — | 60.1% | ||
| Q2 24 | — | 59.0% | ||
| Q1 24 | — | 45.6% |
营业利润率FUSBSSKN
| Q4 25 | 28.1% | 5.3% | ||
| Q3 25 | 23.9% | -16.9% | ||
| Q2 25 | 1.6% | -30.1% | ||
| Q1 25 | 23.8% | -25.0% | ||
| Q4 24 | 23.8% | -44.7% | ||
| Q3 24 | 29.2% | -18.2% | ||
| Q2 24 | 27.4% | -5.7% | ||
| Q1 24 | 27.8% | -42.7% |
净利率FUSBSSKN
| Q4 25 | 20.4% | 0.6% | ||
| Q3 25 | 18.4% | -23.4% | ||
| Q2 25 | 1.5% | -33.6% | ||
| Q1 25 | 18.1% | -31.2% | ||
| Q4 24 | 17.6% | -47.6% | ||
| Q3 24 | 22.0% | -23.6% | ||
| Q2 24 | 21.2% | -1.1% | ||
| Q1 24 | 21.3% | -49.8% |
每股收益（稀释后）FUSBSSKN
| Q4 25 | $0.36 | $0.14 | ||
| Q3 25 | $0.32 | $-0.36 | ||
| Q2 25 | $0.03 | $-0.62 | ||
| Q1 25 | $0.29 | $-0.51 | ||
| Q4 24 | $0.29 | $-2.01 | ||
| Q3 24 | $0.36 | $-0.51 | ||
| Q2 24 | $0.34 | $-0.03 | ||
| Q1 24 | $0.34 | $-0.10 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $73.5M | $7.9M |
| 总债务越低越好 | $10.9M | $15.3M |
| 股东权益账面价值 | $105.6M | $2.9M |
| 总资产 | $1.2B | $30.5M |
| 负债/权益比越低杠杆越低 | 0.10× | 5.28× |
8季度趋势，按日历期对齐
现金及短期投资FUSBSSKN
| Q4 25 | $73.5M | $7.9M | ||
| Q3 25 | $54.7M | $7.1M | ||
| Q2 25 | $54.0M | $6.0M | ||
| Q1 25 | $56.0M | $6.5M | ||
| Q4 24 | $47.2M | $7.3M | ||
| Q3 24 | $82.3M | $7.1M | ||
| Q2 24 | $58.2M | $5.5M | ||
| Q1 24 | $60.2M | $5.2M |
总债务FUSBSSKN
| Q4 25 | $10.9M | $15.3M | ||
| Q3 25 | $10.9M | $15.3M | ||
| Q2 25 | $10.9M | $15.0M | ||
| Q1 25 | $10.9M | $15.0M | ||
| Q4 24 | $10.9M | $15.0M | ||
| Q3 24 | $10.9M | $15.0M | ||
| Q2 24 | $10.8M | $15.0M | ||
| Q1 24 | $10.8M | $15.0M |
股东权益FUSBSSKN
| Q4 25 | $105.6M | $2.9M | ||
| Q3 25 | $104.2M | $1.3M | ||
| Q2 25 | $101.9M | $532.0K | ||
| Q1 25 | $101.2M | $3.0M | ||
| Q4 24 | $98.6M | $5.0M | ||
| Q3 24 | $98.5M | $9.4M | ||
| Q2 24 | $93.8M | $9.5M | ||
| Q1 24 | $92.3M | $9.4M |
总资产FUSBSSKN
| Q4 25 | $1.2B | $30.5M | ||
| Q3 25 | $1.1B | $30.7M | ||
| Q2 25 | $1.1B | $29.5M | ||
| Q1 25 | $1.1B | $33.0M | ||
| Q4 24 | $1.1B | $34.9M | ||
| Q3 24 | $1.1B | $39.4M | ||
| Q2 24 | $1.1B | $38.8M | ||
| Q1 24 | $1.1B | $39.2M |
负债/权益比FUSBSSKN
| Q4 25 | 0.10× | 5.28× | ||
| Q3 25 | 0.10× | 11.65× | ||
| Q2 25 | 0.11× | 28.20× | ||
| Q1 25 | 0.11× | 5.04× | ||
| Q4 24 | 0.11× | 3.02× | ||
| Q3 24 | 0.11× | 1.60× | ||
| Q2 24 | 0.12× | 1.58× | ||
| Q1 24 | 0.12× | 1.59× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $12.3M | $-239.0K |
| 自由现金流经营现金流 - 资本支出 | $9.1M | $-551.0K |
| 自由现金流率自由现金流/营收 | 87.2% | -5.9% |
| 资本支出强度资本支出/营收 | 31.1% | 3.4% |
| 现金转化率经营现金流/净利润 | 5.79× | -4.12× |
| 过去12个月自由现金流最近4个季度 | $16.0M | $-4.4M |
8季度趋势，按日历期对齐
经营现金流FUSBSSKN
| Q4 25 | $12.3M | $-239.0K | ||
| Q3 25 | $4.2M | $-64.0K | ||
| Q2 25 | $3.9M | $-1.9M | ||
| Q1 25 | $1.8M | $-550.0K | ||
| Q4 24 | $7.8M | $703.0K | ||
| Q3 24 | $1.9M | $-302.0K | ||
| Q2 24 | $2.5M | $591.0K | ||
| Q1 24 | $825.0K | $-804.0K |
自由现金流FUSBSSKN
| Q4 25 | $9.1M | $-551.0K | ||
| Q3 25 | $3.6M | $-1.1M | ||
| Q2 25 | $1.6M | $-2.0M | ||
| Q1 25 | $1.7M | $-749.0K | ||
| Q4 24 | $5.7M | $199.0K | ||
| Q3 24 | $1.3M | $-364.0K | ||
| Q2 24 | $2.3M | $246.0K | ||
| Q1 24 | $-142.0K | $-1.5M |
自由现金流率FUSBSSKN
| Q4 25 | 87.2% | -5.9% | ||
| Q3 25 | 34.2% | -15.6% | ||
| Q2 25 | 16.0% | -26.1% | ||
| Q1 25 | 17.2% | -11.0% | ||
| Q4 24 | 58.2% | 2.1% | ||
| Q3 24 | 12.7% | -4.1% | ||
| Q2 24 | 23.5% | 2.9% | ||
| Q1 24 | -1.4% | -22.6% |
资本支出强度FUSBSSKN
| Q4 25 | 31.1% | 3.4% | ||
| Q3 25 | 5.9% | 14.7% | ||
| Q2 25 | 21.8% | 0.8% | ||
| Q1 25 | 0.7% | 2.9% | ||
| Q4 24 | 21.6% | 5.3% | ||
| Q3 24 | 6.6% | 0.7% | ||
| Q2 24 | 2.0% | 4.1% | ||
| Q1 24 | 9.8% | 10.7% |
现金转化率FUSBSSKN
| Q4 25 | 5.79× | -4.12× | ||
| Q3 25 | 2.18× | — | ||
| Q2 25 | 25.16× | — | ||
| Q1 25 | 0.99× | — | ||
| Q4 24 | 4.53× | — | ||
| Q3 24 | 0.87× | — | ||
| Q2 24 | 1.20× | — | ||
| Q1 24 | 0.39× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
FUSB
暂无分部数据
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
